(Total Views: 152)
Posted On: 05/04/2022 10:04:11 AM
Post# of 10156
During the interview Mr. Carrick updated current and prospective shareholders on recent milestones achieved by the Company including:
Nascent is at the leading edge of natural, patient-derived monoclonal antibody development with the Company's PTB monoclonal antibody solution benefitting from a well-defined regulatory and clinical development strategy toward the treatment of deadly brain cancers.
The vaccine development platform, using A recombinant Bacillus Calmette-Guerin (r-BCG), continues to progress and is intended to be used against viruses around the world.
https://www.accesswire.com/699981/Nascent-Bio...-Investors
Nascent is at the leading edge of natural, patient-derived monoclonal antibody development with the Company's PTB monoclonal antibody solution benefitting from a well-defined regulatory and clinical development strategy toward the treatment of deadly brain cancers.
The vaccine development platform, using A recombinant Bacillus Calmette-Guerin (r-BCG), continues to progress and is intended to be used against viruses around the world.
https://www.accesswire.com/699981/Nascent-Bio...-Investors
(0)
(0)
